POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
BEIJING, CHINA and CAMBRIDGE, MASSACHUSETTS, US – (January 18, 2021) – EdiGene, Inc. ( “Company”,...SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ...January 8th,2021, Shanghai—Abbisko Therapeutics Co., Ltd. announced the recent completion of its...HONG KONG and SUZHOU, China, and HANGZHOU, China, Dec. 23, 2020 /PRNewswire/ -- Transcenta...2020年12月21日December 21, 2020 – Jacobio Pharmaceuticals, a clinical-stage biotech company focusing on the in...SHANGHAI--(BUSINESS WIRE)--SciNeuro Pharmaceuticals (www.scineuro.com), focused on developing...Proceeds to fund development of novel and best-in-class therapeutics for eye diseasesCharles...November 9, 2020 – RemeGen, a Yantai, Shandong-based biotech, debuted on Hong Kong Stock Exchange...More Posts
Company
Shanghai
Room2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Unit 902-904, Two ChinaChem Central, 26 Des Voeux Road Central, Hong Kong
US
2730 Sand Hill Road, Suite 130, Menlo Park, CA
All Posts
×
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
http://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png